Safe preparation and administration of intravitreal bevacizumab injections

New England Journal of Medicine

Volumn 365, Issue 23, 2011, Pages 2238-

  Frost, Beth Anne ^a   Kainer, Marion A ^a  

^a TENNESSEE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ALPHA HEMOLYTIC STREPTOCOCCUS; BACTERIUM CONTAMINATION; DRUG ADMINISTRATION; DRUG CONTAMINATION; DRUG SAFETY; ENDOPHTHALMITIS; LETTER; MASK; PHARMACY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; UNITED STATES;

EID: 83155188423     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1105759     Document Type: Letter

References (4)

1. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
2. Frost BA, Kainer MA. Eye opening: are compounding pharmacies causing harm? Presented at the Society for Healthcare Epidemiology of America 2011 Annual Scientific Meeting, Dallas, April 1-4, 2011 (http://www.ismp.org/docs/ paper4263.pdf).
3. General chapter 797: pharmaceutical compounding - sterile preparations. In: Revisions to USP 31-NF 26, second supplement. Rockville, MD: The United States Pharmacopeial Convention, 2008 (http://www.usp.org/products/797Guidebook) .
4. Preventing unsafe injection practices. Atlanta: Centers for Disease Control and Prevention (http://www.cdc.gov/injectionsafety/ unsafePractices. html).